Clinical Trials on 慢性阻塞性肺疾病 in New Zealand
总计5352个结果
-
University of OtagoHealth Research Council, New Zealand完全的
-
Fisher and Paykel HealthcareMedical Research Institute of New Zealand; Alana Healthcare终止
-
GlaxoSmithKline完全的
-
Mundipharma Research Limited完全的
-
Teva Branded Pharmaceutical Products R&D, Inc.终止
-
Teva Branded Pharmaceutical Products R&D, Inc.终止慢性阻塞性肺疾病美国, 澳大利亚, 新西兰
-
Novartis完全的
-
Pearl Therapeutics, Inc.完全的
-
Dey完全的
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)主动,不招人
-
GlaxoSmithKline完全的
-
Turino, Gerard, M.D.National Heart, Lung, and Blood Institute (NHLBI)完全的
-
Boehringer Ingelheim完全的
-
Columbia UniversityNational Institute of Environmental Health Sciences (NIEHS)完全的
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company (BI); DARTNet Institute 和其他合作者未知
-
AstraZeneca完全的
-
Pulmatrix Inc.The VA Western New York Healthcare System; Buffalo Institute For Medical Research完全的
-
The George InstituteNational Health and Medical Research Council, Australia完全的
-
Convexity Scientific IncCOPD Foundation完全的
-
GlaxoSmithKline完全的
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI)完全的
-
Novartis Pharmaceuticals完全的慢性阻塞性肺疾病 (COPD)美国, 哥伦比亚, 阿根廷, 德国, 西班牙, 火鸡, 危地马拉, 墨西哥, 澳大利亚, 丹麦, 南非, 菲律宾